X

Drug Profile

MPC 0767 - Myrexis

Alternative Names: MPC-0767 - Myrexis

Latest Information Update: 05 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Myrexis
Class Purines; Small molecules
Mechanism of Action HSP90 heat-shock protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Cancer

Most Recent Events

28 Feb 2014 Discontinued - Preclinical for Cancer in USA (PO)
09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
29 Feb 2012 Suspended - Preclinical for Cancer in USA (PO) (Myrexix pipeline, February 2012)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com